Skip to content

The Use of Diffuse Optical Spectroscopy to Characterize in Response to Weight-Loss Intervention

The Use of Diffuse Optical Spectroscopy to Characterize Adipose Tissue Oxygenation and Vascular Reactivity in Response to Weight-Loss Intervention

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02146885
Enrollment
21
Registered
2014-05-26
Start date
2013-01-08
Completion date
2017-01-13
Last updated
2022-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Overweight

Brief summary

The first step in any clinical intervention against obesity involves sustained lifestyle changes. Researcher can use these strategies to beneficial the effects of weight and on cardiovascular risk. The researcher develope methods for assessing the effectiveness use optical technology to make such assessments, specifically in the area of fatty tissue can predict the effectiveness of the intervention in causing weight reduction and treating metabolic disease.

Detailed description

Optical technologies under development at the Beckman Laser Institute. Diffuse Optical Spectroscopy Imaging is a method for studying absorption and scattering (optical properties) of tissue in humans. It is related to near-infrared spectroscopy , but allows for more quantitative and thorough measurements. The researcher use Diffuse Optical Spectroscopy to measure fatty tissue, water, blood concentration level during weight loss program to determine the effect of sustained changes in weight or relapses.

Interventions

OTHERWeight Control

Weight Control

Sponsors

Beckman Laser Institute University of California Irvine
CollaboratorOTHER
University of California, Irvine
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Body Mass Index greater than 25, overweight * Participation in Weight Loss program

Exclusion criteria

* A medical history of myocardial infarction or cerebrovascular stroke * Pregnancy or planned pregnancy during the course of the study period

Design outcomes

Primary

MeasureTime frame
Weight Control3 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026